Yes. MEA assays are widely used in CNS drug discovery to assess functional efficacy, dose–response relationships, and potential neurotoxic effects using human-relevant neuronal models. They enable scalable, longitudinal measurement of neuronal network activity, making them well suited for both early-stage screening and mechanistic studies.